Frontline Immunotherapy/Bevacizumab Ups PFS in PD-L1–Positive mRCC

Video

This video examines a phase II study that compared atezolizumab with or without bevacizumab vs sunitinib in untreated patients with metastatic renal cell carcinoma.

In this video, David F. McDermott, MD, of Beth Israel Deaconess Medical Center in Boston, discusses a phase II study (IMmotion 150) that compared the anti–PD-L1 agent atezolizumab with or without bevacizumab vs sunitinib in untreated patients with metastatic renal cell carcinoma (mRCC).

With a median follow-up of 20.7 months, results of the study showed a median progression-free survival (PFS) of 14.7 months in PD-L1–positive mRCC patients who received atezolizumab/bevacizumab vs 7.8 months in patients on sunitinib alone (hazard ratio, 0.64; 95% CI, 0.38–1.08).

McDermott highlights interesting findings from the study, including patients who achieved complete responses, and notable adverse events from the combination regimen.

The study (abstract 431) was presented at the 2017 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, held February 16–18 in Orlando, Florida.

Recent Videos
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content